Advances in Insulin Pump Infusion Sets Symposium Report
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Advances in Insulin Pump Infusion Sets Symposium Report. / Zhang, Jennifer Y.; Shang, Trisha; Chattaraj, Sarnath; Cohen, Ohad; Heschel, Matthias; Vigersky, Robert A.; Heinemann, Lutz; Nørgaard, Kirsten; Svensson, Jannet; Buckingham, Bruce; Klonoff, David C.
In: Journal of Diabetes Science and Technology, Vol. 15, No. 3, 2021, p. 705-709.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Advances in Insulin Pump Infusion Sets Symposium Report
AU - Zhang, Jennifer Y.
AU - Shang, Trisha
AU - Chattaraj, Sarnath
AU - Cohen, Ohad
AU - Heschel, Matthias
AU - Vigersky, Robert A.
AU - Heinemann, Lutz
AU - Nørgaard, Kirsten
AU - Svensson, Jannet
AU - Buckingham, Bruce
AU - Klonoff, David C.
N1 - Publisher Copyright: © 2021 Diabetes Technology Society.
PY - 2021
Y1 - 2021
N2 - Continuous subcutaneous insulin infusion (CSII) is becoming increasingly used for achieving target glycemic control as well as providing flexibility in lifestyle. In a widely used version of CSII, the insulin pump itself is attached to one end of an insulin infusion set (IIS), which delivers insulin via a thin flexible plastic tube to the patient’s body via a cannula or needle that is inserted under the skin at the other end of the IIS. Despite the increased use of CSII by patients with diabetes, there have been few recent advances in IIS technology, especially when compared to the many recent advances made in insulin pump technology and in insulin pharmacokinetics. To discuss recent developments in, and future plans for IIS development, Diabetes Technology Society virtually hosted the Advances in Insulin Pump Infusion Sets Symposium on December 1, 2020. This symposium featured experts in the field of IISs, including representatives from Medtronic and ConvaTec (which are two manufacturers that are currently developing IISs), Stanford University, Steno Diabetes Center Copenhagen, and Science Consulting in Diabetes. The webinar’s six speakers covered (1) patient burden, (2) extended wear technology, and (3) future directions in IIS development.
AB - Continuous subcutaneous insulin infusion (CSII) is becoming increasingly used for achieving target glycemic control as well as providing flexibility in lifestyle. In a widely used version of CSII, the insulin pump itself is attached to one end of an insulin infusion set (IIS), which delivers insulin via a thin flexible plastic tube to the patient’s body via a cannula or needle that is inserted under the skin at the other end of the IIS. Despite the increased use of CSII by patients with diabetes, there have been few recent advances in IIS technology, especially when compared to the many recent advances made in insulin pump technology and in insulin pharmacokinetics. To discuss recent developments in, and future plans for IIS development, Diabetes Technology Society virtually hosted the Advances in Insulin Pump Infusion Sets Symposium on December 1, 2020. This symposium featured experts in the field of IISs, including representatives from Medtronic and ConvaTec (which are two manufacturers that are currently developing IISs), Stanford University, Steno Diabetes Center Copenhagen, and Science Consulting in Diabetes. The webinar’s six speakers covered (1) patient burden, (2) extended wear technology, and (3) future directions in IIS development.
KW - adhesive
KW - diabetes
KW - infusion set
KW - insulin
KW - occlusion
KW - pump
U2 - 10.1177/1932296821999080
DO - 10.1177/1932296821999080
M3 - Journal article
C2 - 33703930
AN - SCOPUS:85102714065
VL - 15
SP - 705
EP - 709
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
IS - 3
ER -
ID: 301140385